CoPlex Signs License Agreement to To Develop Possible Alzheimer's Treatment (IMAGE)

University of Kentucky

CoPlex Signs License Agreement to To Develop Possible Alzheimer's Treatment

Caption

University of Kentucky spinoff company CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.

Credit

University of Kentucky

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.